S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
Log in

NASDAQ:CUTR - Cutera Stock Price, Forecast & News

$37.30
+0.33 (+0.89 %)
(As of 12/10/2019 04:00 PM ET)
Today's Range
$35.98
Now: $37.30
$37.34
50-Day Range
$28.20
MA: $34.74
$38.83
52-Week Range
$12.32
Now: $37.30
$39.15
Volume107,955 shs
Average Volume171,436 shs
Market Capitalization$530.89 million
P/E RatioN/A
Dividend YieldN/A
Beta0.96
Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:CUTR
CUSIPN/A
Phone415-657-5500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$162.72 million
Book Value$3.34 per share

Profitability

Net Income$-30,770,000.00

Miscellaneous

Employees402
Market Cap$530.89 million
Next Earnings Date2/19/2020 (Estimated)
OptionableOptionable

Receive CUTR News and Ratings via Email

Sign-up to receive the latest news and ratings for CUTR and its competitors with MarketBeat's FREE daily newsletter.


Cutera (NASDAQ:CUTR) Frequently Asked Questions

What is Cutera's stock symbol?

Cutera trades on the NASDAQ under the ticker symbol "CUTR."

How were Cutera's earnings last quarter?

Cutera, Inc. (NASDAQ:CUTR) released its earnings results on Thursday, November, 7th. The medical device company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.23. The medical device company had revenue of $46.12 million for the quarter, compared to analyst estimates of $41.66 million. Cutera had a negative net margin of 20.84% and a negative return on equity of 84.67%. The business's quarterly revenue was up 13.7% compared to the same quarter last year. During the same period last year, the firm earned $0.11 EPS. View Cutera's Earnings History.

When is Cutera's next earnings date?

Cutera is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Cutera.

What guidance has Cutera issued on next quarter's earnings?

Cutera issued an update on its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$177-179 million, compared to the consensus revenue estimate of $$175.35 million.

What price target have analysts set for CUTR?

3 brokerages have issued twelve-month target prices for Cutera's shares. Their forecasts range from $45.00 to $45.00. On average, they anticipate Cutera's share price to reach $45.00 in the next twelve months. This suggests a possible upside of 20.6% from the stock's current price. View Analyst Price Targets for Cutera.

What is the consensus analysts' recommendation for Cutera?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cutera in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cutera.

What are Wall Street analysts saying about Cutera stock?

Here are some recent quotes from research analysts about Cutera stock:
  • 1. According to Zacks Investment Research, "Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. " (11/13/2019)
  • 2. Maxim Group analysts commented, "Market close, CUTR reported better-than-expected 2Q19 revenue, earnings, and gross margin compared to both Maxim and consensus estimates. Due to strong sales during the quarter and higher expected gross margins going forward, we are increasing our 2019 and 2020 revenue and GAAP EPS estimates. Management reiterated 2019 guidance for revenue, gross margins, and adjusted EBITDA, which we believe may now be too conservative in terms of revenue. We are also introducing quarterly estimates for 2020." (8/9/2019)

Has Cutera been receiving favorable news coverage?

Media headlines about CUTR stock have trended negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cutera earned a daily sentiment score of -2.5 on InfoTrie's scale. They also gave news stories about the medical device company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Cutera.

Are investors shorting Cutera?

Cutera saw a decrease in short interest in the month of November. As of November 15th, there was short interest totalling 800,100 shares, a decrease of 10.6% from the October 31st total of 895,100 shares. Based on an average daily trading volume, of 165,300 shares, the short-interest ratio is currently 4.8 days. Approximately 5.9% of the company's stock are short sold. View Cutera's Current Options Chain.

Who are some of Cutera's key competitors?

What other stocks do shareholders of Cutera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cutera investors own include AbbVie (ABBV), Alibaba Group (BABA), Micron Technology (MU), Celgene (CELG), Pfizer (PFE), Clovis Oncology (CLVS), Costco Wholesale (COST), Exelixis (EXEL), FLIR Systems (FLIR) and Gilead Sciences (GILD).

Who are Cutera's key executives?

Cutera's management team includes the folowing people:
  • Ms. Sandra A. Gardiner, Exec. VP & CFO (Age 53)
  • Mr. Larry E. Laber, Exec. VP of Sales - North America (Age 48)
  • Mr. Ronald J. Santilli, Exec. Officer (Age 59)
  • Mr. Jason Richey, Interim CEO & Chief Operating Officer
  • Dr. Michael Karavitis, Exec. VP & Chief Technology Officer

Who are Cutera's major shareholders?

Cutera's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Gamco Investors INC. ET AL (7.81%), Gabelli Funds LLC (4.50%), State Street Corp (3.27%), Teton Advisors Inc. (2.72%), Assenagon Asset Management S.A. (2.30%) and Essex Investment Management Co. LLC (1.24%). Company insiders that own Cutera stock include David A Gollnick, David B Apfelberg, Gregory A Barrett, J Daniel Plants, James A Reinstein, Larry Laber and Miguel Pardos. View Institutional Ownership Trends for Cutera.

Which institutional investors are selling Cutera stock?

CUTR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Lapides Asset Management LLC, Gamco Investors INC. ET AL, Squarepoint Ops LLC, Gabelli Funds LLC, Quantum Capital Management, Teton Advisors Inc. and Stephens Inc. AR. View Insider Buying and Selling for Cutera.

Which institutional investors are buying Cutera stock?

CUTR stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Mackay Shields LLC, Assenagon Asset Management S.A., Wedge Capital Management L L P NC, Essex Investment Management Co. LLC, Calamos Advisors LLC, Russell Investments Group Ltd. and New York State Teachers Retirement System. Company insiders that have bought Cutera stock in the last two years include Gregory A Barrett, J Daniel Plants and James A Reinstein. View Insider Buying and Selling for Cutera.

How do I buy shares of Cutera?

Shares of CUTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cutera's stock price today?

One share of CUTR stock can currently be purchased for approximately $37.30.

How big of a company is Cutera?

Cutera has a market capitalization of $530.89 million and generates $162.72 million in revenue each year. The medical device company earns $-30,770,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Cutera employs 402 workers across the globe.View Additional Information About Cutera.

What is Cutera's official website?

The official website for Cutera is http://www.cutera.com/.

How can I contact Cutera?

Cutera's mailing address is 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The medical device company can be reached via phone at 415-657-5500 or via email at [email protected]


MarketBeat Community Rating for Cutera (NASDAQ CUTR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  284 (Vote Outperform)
Underperform Votes:  263 (Vote Underperform)
Total Votes:  547
MarketBeat's community ratings are surveys of what our community members think about Cutera and other stocks. Vote "Outperform" if you believe CUTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel